Elicio Therapeutics (ELTX) Corporate presentation summary

Investment highlights

• Developing novel, off-the-shelf cancer immunotherapies targeting lymph nodes using proprietary Amphiphile (AMP) technology for robust and durable immune responses.

• ELI-002 targets the most common KRAS mutations, covering 25% of solid tumors, with potential as a monotherapy in high relapse-risk pancreatic (PDAC) and colorectal cancers (CRC).

• Phase 2 trial of ELI-002 7P in PDAC showed >44x increase in mKRAS-specific T cell response over baseline, with no dose-limiting toxicities or serious adverse events.

• Phase 1 data: ELI-002 2P cohort (n=25) achieved median overall survival (mOS) of 28.9 months and median relapse-free survival (mRFS) of 16.3 months.

• Cash runway supports operations through Q2 2026, beyond expected Phase 2 final data analysis in 1H 2026.

Clinical pipeline and technology

• Pipeline includes ELI-002 (mKRAS), ELI-004 (soft tissue sarcoma), ELI-007 (mBRAF), and ELI-008 (mp53), with multiple programs advancing toward clinical readiness.

• AMP platform enables targeted delivery of immune therapeutics to lymph nodes, enhancing antigen-specific T cell responses and antigen spreading.

• ELI-002 7P demonstrated robust T cell activation (median 113.3x fold change) and antigen spreading to personalized tumor neoantigens in Phase 1.

• Phase 2 data confirm consistent, strong mKRAS-specific T cell responses across diverse HLA backgrounds, supporting broad applicability.

• ELI-002 7P was well tolerated with no dose-limiting toxicities; most common adverse events were mild fatigue and malaise.

Market opportunity and clinical results

• ELI-002 7P addresses a significant market: ~48K PDAC and ~88K additional patients annually in major markets, with a total addressable market of ~$11.5B (adjuvant) and ~$27B (systemic) for PDAC alone.

• Beyond PDAC, ELI-002 7P targets CRC (~210K incidence, ~$50B TAM) and NSCLC (~120K incidence, ~$28B TAM).

• Phase 1 trials showed 84–100% of patients generated robust mKRAS-specific T cell responses, correlating with tumor biomarker declines and improved relapse-free and overall survival.

• Patients with above-threshold T cell responses had an 88% reduced risk of relapse or death and a 77% reduced risk of death compared to those below threshold.

• Phase 2 interim analysis completed; final disease-free survival analysis expected in 1H 2026, with Phase 3 design aligned with FDA feedback.